Clinical trial Recruiting at 3 sites Observational Ages 18 and up

Understanding how aortic stenosis progresses and who is at risk

Official title: Evaluation of Immunologic and Image Morphologic Parameters to Predict Disease Progression in Patients With Moderate Aortic Valve Stenosis

Run by Heinrich-Heine University, Duesseldorf · NCT05851209 · Data updated 2026-11-12

This study tests whether imaging, genetic, and immune markers can predict which people with moderate aortic valve narrowing will quickly develop severe disease.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment938 (estimated)
SponsorHeinrich-Heine University, Duesseldorf
Academic / other
Locations3 sites (Bonn and 2 other locations)
StatusRecruiting
StartedJuly 1, 2023
Main results expectedJuly 2026
Study endsJuly 2031
Registry record updatedJune 30, 2026
Trial IDNCT05851209 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with acquired moderate tricuspid aortic valve stenosis under regular cardiology care.

Probably not a fit

Patients with mild or very advanced disease, bicuspid valves, or contraindications to MRI/CT may not benefit from the study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study follows a large cohort of adults with moderate aortic stenosis to identify biomarkers and imaging features that predict progression to severe disease. Researchers will analyze morphological, functional, genetic, and immunological data to see which factors best forecast worsening valve function. The goal is to identify high-risk patients who might benefit from earlier intervention and to explore options to slow progression. The study builds on previous work showing inflammation and calcification play roles in aortic valve disease.

Why it matters

Potential benefit: If successful, the study could improve early risk stratification and inform timing of treatment to prevent adverse outcomes.

How similar studies have gone: Prior work suggests inflammatory and imaging markers can relate to disease progression, supporting the approach but the specific predictive model is being tested here.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* The patient has an acquired (tricuspid) moderate aortic valve stenosis, which is the reason for regular outpatient cardiological care.
* The subject has been informed verbally and in writing about the study and has given written consent to participate in this study.
* Age \> 18 years

Exclusion Criteria:

* The subject has contraindications for the performance of a magnetic resonance imaging or computed tomography (e.g., severe arrhythmias , contrast agent intolerance, a pacemaker, or severe renal insufficiency or severe renal insufficiency or claustrophobia).
* Presence of only mild or already high-grade acquired tricuspid Aortic valve stenosis
* Patient with bicuspid aortic valve
* Inability to follow the instructions of study personnel
* Lack of written informed consent

Where it's running

  • University-Hospital Bonn
    Bonn, Germany
    Recruiting
  • University Hospital Cologne
    Cologne, Germany
    Recruiting
  • University-Hospital Düsseldorf Division of Cardiology, Pulmonary Disease and Vascular Medicine
    Düsseldorf, Germany
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.